The initiative is to provide research and development services for discovery and early drug development, Biocon said here on Wednesday.
Bristol-Myers Squibb will significantly increase the scope of its existing relationship with Syngene to develop integrated capabilities in medicinal chemistry, biology, drug metabolism and pharmaceutical development.
The partnership will include a dedicated research facility at the Biocon Park here which will eventually house a team of 400 scientists.
Biocon Chairperson, Kiran Mazumdar-Shaw, said, "The new research facility will take us forward in our evolution as a vaulable partner to the global pharma industry. Syngene has advanced capabilities in high-end services in discovery research." This one-of-its kind alliance in the biotech sector will leverage the current global demand for `bio-partnering' and access to top scientific talent in India for the overseas partner.
Chief Scientific Officer and President, Pharmaceutical Research, Bristol-Myers Squibb, Elliott Sigal, said, "This broad expansion of R&D in India will allow us to grow competitively and provide access to world-class talent to deliver and grow our robust product pipeline."
Syngene International is a custom research company that does research for client companies across the world and has multi-disciplinary skills in synthetic chemistry and molecular biology. It also leverages the convergence of information technology and biotechnology to conduct early stage drug discovery and was started in 1994.
